|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007102,
umls-concept:C0069515,
umls-concept:C0086418,
umls-concept:C0242957,
umls-concept:C0334227,
umls-concept:C0376525,
umls-concept:C0441655,
umls-concept:C1328025,
umls-concept:C1515655,
umls-concept:C1533691,
umls-concept:C1999216
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2009-8-18
|
|
pubmed:abstractText |
The monoclonal antibody pertuzumab represents the first HER2 dimerization inhibitor with unknown activity in colon cancer treatment. We examined the antitumor activity of pertuzumab as a single agent or in combination with erlotinib or irinotecan in human colon cancer cells in vitro and in vivo.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Camptothecin,
http://linkedlifedata.com/resource/pubmed/chemical/Epidermal Growth Factor,
http://linkedlifedata.com/resource/pubmed/chemical/HER2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Quinazolines,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2,
http://linkedlifedata.com/resource/pubmed/chemical/erlotinib,
http://linkedlifedata.com/resource/pubmed/chemical/irinotecan,
http://linkedlifedata.com/resource/pubmed/chemical/pertuzumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1432-1335
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
135
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1377-86
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19340455-Animals,
pubmed-meshheading:19340455-Antibodies, Monoclonal,
pubmed-meshheading:19340455-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:19340455-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19340455-Blotting, Western,
pubmed-meshheading:19340455-Camptothecin,
pubmed-meshheading:19340455-Cell Cycle,
pubmed-meshheading:19340455-Cell Line, Tumor,
pubmed-meshheading:19340455-Colorectal Neoplasms,
pubmed-meshheading:19340455-Dimerization,
pubmed-meshheading:19340455-Drug Therapy, Combination,
pubmed-meshheading:19340455-Epidermal Growth Factor,
pubmed-meshheading:19340455-Female,
pubmed-meshheading:19340455-Humans,
pubmed-meshheading:19340455-Mice,
pubmed-meshheading:19340455-Mice, Nude,
pubmed-meshheading:19340455-Protein Multimerization,
pubmed-meshheading:19340455-Quinazolines,
pubmed-meshheading:19340455-Receptor, erbB-2,
pubmed-meshheading:19340455-Xenograft Model Antitumor Assays
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo.
|
|
pubmed:affiliation |
Department of Medicine, Knappschaftskrankenhaus, Ruhr University, In der Schornau 23-25, 44892 Bochum, Germany. Michael.Pohl-4@rub.de
|
|
pubmed:publicationType |
Journal Article,
In Vitro,
Research Support, Non-U.S. Gov't
|
